1 November 2006 in Australian & New Zealand Journal of Psychiatry
Objectives: To examine the validity and reliability of a brief cognitive screen instrument, the Neuropsychiatry Unit Cognitive Assessment Tool (NUCOG), in patients with dementia, major psychiatric disorders and neurological disorders, and to compare its performance with the Mini-Mental State Examination (MMSE). Method: The NUCOG was undertaken with the MMSE on a total of 347 individuals, with 82 subjects in the control group and 265 in the patient group. The patient group consisted of patients with dementia (n = 65), non-dementing neurological disorders (n = 44) and psychiatric illness (n = 156). The patient group was further broken into subgroups of dementing and psychiatric disorders for further analysis. A subgroup of patients (n = 22) underwent detailed neuropsychological testing. Results: The NUCOG and MMSE scores, which correlated strongly, were highest in the control group, and lowest in the dementia group, with psychiatric and neurological patients scoring similarly. Internal consistency and reliability were high. Scores were significantly affected by age and years of education. The NUCOG differentiated the four broad groups and the dementia subgroups more strongly than the MMSE. The NUCOG subscale scores correlated strongly with most neuropsychological subtests undertaken. At a cut-off score of 80/100, sensitivity of the NUCOG for detection of dementia was 0.84 and specificity 0.86. Conclusions: The NUCOG is a valid and reliable cognitive tool that is sensitive and specific for the detection of dementia. The NUCOG was able to differentiate dementia and psychiatric subgroups which were not able to be discriminated on MMSE scores. The NUCOG appears to be a well-tolerated, reliable and highly useful clinical tool that offers benefits over and above the MMSE.
11 October 2016 in Neurology
22 September 2015 in Neurology
21 September 2023 in Clinical Case Reports
Key Clinical Message: Consider the differential of Epstein–Barr virus (EBV) reactivation in pregnant women who develop progressive meningoencephalitis and transverse myelitis. EBV nucleic acid amplification should be considered in immunosuppressed patients. A 32‐year‐old G10P6M3K22 pregnant female presented to a regional hospital with progressive severe neurological and behavioral deficits. Magnetic resonance revealed cervical transverse myelitis. Lumbar puncture confirmed Epstein–Barr virus (EBV) DNA on a background of IgG‐positive EBV serology. A diagnosis of EBV reactivation‐related meningoencephalitis with transverse myelitis in pregnancy was concluded.
5 April 2016 in Neurology